I am a
Home I AM A Search Login

Papers of the Week

Papers: 26 Feb 2022 - 4 Mar 2022

Pharmacology/Drug Development

2022 Feb 17

J Clin Med



The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review.


Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G
J Clin Med. 2022 Feb 17; 11(4).
PMID: 35207315.


Irritable bowel syndrome (IBS) is a common gastrointestinal tract disorder, affecting 10-20% of adults worldwide. Mebeverine is an antispasmodic agent indicated for the symptomatic treatment of abdominal pain caused by intestinal smooth muscle spasms and intestinal functional disorders in the course of IBS. The aim of this article was to perform a systematic literature review and update previous overviews of the efficacy and safety of mebeverine treatment in IBS.